

December 14, 2018

**British Columbia Securities Commission
Alberta Securities Commission
Ontario Securities Commission**

Dear Sirs / Mesdames:

Re: Medicenna Therapeutics Corp.

We refer to the short form prospectus of Medicenna Therapeutics Corp. (the "Company") dated December 14, 2018 relating to the sale and issue of units of the Company.

We consent to being named and to the use, through incorporation by reference in the above-mentioned short form prospectus, of our report dated June 26, 2018 to the shareholders of the Company on the following financial statements:

Consolidated statements of financial position as at March 31, 2018 and 2017;

Consolidated statements of operations, changes in shareholders' equity and cash flows for the years ended March 31, 2018 and 2017, and a summary of significant accounting policies and other explanatory information.

We report that we have read the short form prospectus and all information specifically incorporated by reference therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the consolidated financial statements upon which we have reported or that are within our knowledge as a result of our audit of such consolidated financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the short form prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Yours very truly,



DAVIDSON & COMPANY LLP
Chartered Professional Accountants

